SCHEMBL1875722

SCHEMBL1875722

COc1ccc(-c2noc(NC(=O)Cc3ccccc3)c2-c2ccncn2)cc1OC

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 15/20 0.71
MAPK9 P45984 1/20 0.51
MAPK10 P53779 1/20 0.51
MAPK11 Q15759 1/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
AAK1 Q2M2I8 1/20 0.49
NOX1 Q9Y5S8 1/20 0.46
CYP3A4 P08684 1/20 0.45
PRKACA P17612 1/20 0.45
ROCK1 Q13464 1/20 0.45
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1874432 0.93 MAPK14 (0.69) MAPK14MAPK9MAPK10MAPK11MEN1
SCHEMBL4335472 0.89 MAPK14 (0.69) MAPK14MEN1KMT2AAAK1KDM4E
SCHEMBL1882630 0.88 MAPK14 (0.78) MAPK14MAPK9MAPK10MAPK11CYP3A4
SCHEMBL1875627 0.88 MAPK14 (0.75) MAPK14MAPK9MAPK10MAPK11KMT2A
SCHEMBL1875193 0.88 MAPK14 (0.75) MAPK14MAPK9MAPK10MAPK11MEN1
SCHEMBL1877952 0.88 MAPK14 (0.68) MAPK14MAPK9MAPK10MAPK11KMT2A
SCHEMBL1876304 0.87 MAPK14 (0.76) MAPK14MAPK9MAPK10MAPK11MEN1
SCHEMBL1878402 0.86 MAPK14 (0.75) MAPK14MAPK9MAPK10MAPK11MEN1
SCHEMBL1882526 0.86 MAPK14 (0.86) MAPK14MAPK9MAPK10MAPK11MEN1
SCHEMBL1880828 0.86 MAPK14 (0.86) MAPK14MAPK9MAPK10MAPK11MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1832584-B1 PYRIMIDINYLISOXAZOLE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-12-21 EP disclosed
US-7939536-B2 5-[(2-chlorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole; p 38MAP kinase inhibitor; tumor necrosis factor, interleukin, or cyclooxygenase-II related diseases; antiinflammatory, anticarcinogenic, antidiabetic agent ASKA PHARMACEUTICAL CO., LTD. (JP) 2011-05-10 US disclosed
US-20080114003-A1 Pyrimidinylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2008-05-15 US disclosed
EP-1832584-A1 PYRIMIDINYLISOXAZOL DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2007-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114003-A1 Pyrimidinylisoxazole Derivatives MAPK3, MAPK7, MAP3K7 MAPK14 29/4885MAPK9 20/4885MAPK10 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.